OSLO, Norway, Oct. 6, 2021 /PRNewswire/ -- Targovax
ASA (OSE: TRVX), a clinical stage immuno-oncology company
developing immune activators to target hard-to-treat solid tumors,
today announces that two abstracts has been accepted for poster
presentation at the Society for Immunotherapy of Cancer (SITC)
Annual Meeting.
The abstracts will be released on the SITC website 9 November
14:00 CEST
(www.sitcancer.org/2021/home). The posters are scheduled for
presentation during the SITC congress 12-14
November 2021.
|
Poster
title:
|
A randomised
open-label phase I/II study adding ONCOS-102 to
pemetrexed/cisplatin in patients with unresectable malignant
pleural mesothelioma – 24-month survival
data
|
|
E-poster
number:
|
462
|
|
Lead
author:
|
Dr Luis Paz-Ares,
Medical Oncology, Hospital Universitario 12 Octubre, Madrid,
Spain
|
***
|
Poster
title:
|
Consistent pattern of
immune activation induced by oncolytic adenovirus ONCOS-102 across
diverse types of solid
tumors
|
|
E-poster
number:
|
368
|
|
Lead
author:
|
Lukasz Kuryk, PhD,
Director Clinical Science,
Targovax
|
***
About SITC
The Society for Immunotherapy of Cancer (SITC) Annual Meeting
& Pre-Conference Programs brings together stakeholders across
the cancer immunotherapy field to advance the science, discover
breakthroughs and educate the world on cancer
immunotherapy.
As the largest conference solely focused on cancer
immunotherapy, the Annual Meeting & Pre-Conference Programs
provides international leaders from academia, regulatory and
government agencies, as well as industry representatives with a
multidisciplinary educational and interactive environment focused
on improving outcomes for all cancer patients.
CONTACT:
For further information, please contact:
Oystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa--two-abstracts-accepted-at-the-sitc-congress,c3428191
